Nectar Lifesciences Profit & Loss Annual

Trade
BSE: 532649 | NSE: NECLIFE | ISIN: INE023H01027 | Sector: Biotechnology & Drugs
33.32 -0.68 (-2.00%)Updated : 25 Nov 2024
Fiscal Period2024202320222021
Period End DateMar 24Mar 23Mar 22Mar 21
Revenue 1,685.631,523.671,668.831,544.37
Total Revenue 1,685.631,523.671,668.831,544.37
Costof Revenue Total 1,202.241,317.401,369.511,285.73
Gross Profit 483.39206.27299.33258.64
Selling/ General/ Admin Expenses Total 84.67153.26140.79148.40
Depreciation/ Amortization 60.7259.1256.9760.25
Other Operating Expenses Total 245.62-0.91--
Total Operating Expense 1,593.251,528.871,567.261,519.69
Operating Income 92.38-5.20101.5724.68
Interest Inc( Exp) Net- Non- Op Total -871.42-809.67-680.57-830.43
Other Net 13.033.34-8.84-26.27
Net Income Before Taxes 18.27-42.4234.08-84.77
Provisionfor Income Taxes 13.27-18.249.03-11.50
Net Income After Taxes 4.99-24.1825.05-73.26
Net Income Before Extra Items 4.99-24.1825.05-73.26
Net Income 4.99-24.1825.05-73.26
Income Availableto Com Excl Extra Ord 4.99-24.1825.05-73.26
Income Availableto Com Incl Extra Ord 4.99-24.1825.05-73.26
Diluted Net Income 4.99-24.1825.05-73.26
Diluted Weighted Average Shares 22.7022.4322.4322.43
Diluted EPS Excluding Extra Ord Items 0.22-1.081.12-3.27
Diluted Normalized EPS 0.22-2.250.81-2.53
Unusual Expense( Income) -0.000.0025.32
Gain( Loss)on Saleof Assets -404.0894.07-1.31
Total Adjustmentsto Net Income --0.01-0.01
DPS- Common Stock Primary Issue ---0.00
*All figures in crores except per share values
Recommended For You
Trending Stocks
3,753.25+148.70(4.13%)
1,784.60+38.65(2.21%)
1,733.95-13.75 (-0.79%)
2,460.60-18.40 (-0.74%)
HomeMarketsPremiumInstant LoanMint Shorts